Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
NCT01964989
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 222, Novartis Investigational Site, Chandler, Arizona +166 locations
Conditions: Influenza Virus
Register for Updates
Adjuvanted Influenza Vaccination in U.S. Nursing Homes
NCT02882100
Completed
This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/14/2023
Locations: Insight Therapeutics, LLC, Norfolk, Virginia
Conditions: Influenza, Influenza-like Illness
Register for Updates
Recombinant Influenza Vaccination in U.S. Nursing Homes
NCT03965195
Unknown
Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause hospitalization.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/14/2023
Locations: Insight Therapeutics, LLC, Norfolk, Virginia
Conditions: Influenza, Influenza -Like Illness, Influenza, Human
Register for Updates
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
NCT02255409
Completed
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
Gender:
ALL
Ages:
Between 12 months and 84 months
Trial Updated:
03/06/2023
Locations: Not set, San Diego, California +27 locations
Conditions: Influenza
Register for Updates
Self-Administered Nasal Influenza Feasibility Study
NCT01933048
Completed
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/13/2023
Locations: Naval Medical Center San Diego, San Diego, California +1 locations
Conditions: Influenza
Register for Updates
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
NCT05268185
Completed
While both heterologous (mixing) and homologous (matching) vaccine regimens are now considered standard of care, post-vaccination complications and long-term effects of the different vaccination regimens have not been thoroughly studied. There is a pressing need to investigate the longitudinal effects of the mixing and matching vaccine-booster approaches. This study proposes to utilize the existing digital infrastructure of the COVID-19 Citizen Science (CCS) study on the Eureka Research Platform... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: UCSF Parnassus, San Francisco, California
Conditions: COVID-19, Vaccine Reaction, COVID-19 Pandemic
Register for Updates
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
NCT01176461
Completed
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine. The purpose of this study is to test the side effects of an investigational vaccine with an immune booster. Investigators also wish to find out its effects on the patient's immune system and whether it will shrink their melanoma.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/17/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Melanoma (Skin)
Register for Updates
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
NCT03620162
Completed
The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV immunization schedule.
Gender:
ALL
Ages:
Between 42 days and 90 days
Trial Updated:
01/12/2023
Locations: Alabama Clinical Therapeutics ( Site 0015), Birmingham, Alabama +33 locations
Conditions: Pneumococcal Infections
Register for Updates
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
NCT03012100
Active Not Recruiting
This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide work to prevent the recurrence of stage 1-3 triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +11 locations
Conditions: Bilateral Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage II Breast Cancer AJCC v6 and v7
Register for Updates
Safety of RIV4 Versus IIV4 in Pregnant Women
NCT03969641
Completed
This is a prospective, randomized clinical trial. During the study, pregnant women will be randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed providers. Prior influenza vaccine history will be verified by medical record review when possible. Injection-site (local) and systemic reaction data will be assessed on vaccination day and during the 8 days following vaccination using either identical web-based or paper diaries, depending on study participant preference.... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2023
Locations: Boston Medical Center, Boston, Massachusetts +2 locations
Conditions: Safety, Adverse Event Following Immunisation, Birth Outcomes
Register for Updates
Tdap Vaccine Safety for Plasma Donors
NCT04142983
Completed
This is a prospective, open label, single-arm, multi-center, Phase 1 study measuring the safety and tetanus antibody responses to Tdap vaccine administered to plasma donors every 3 months ±1 week for 12 months (5 vaccinations) with a 6 month follow-up after the last vaccination. After obtaining informed consent and screening for eligibility including plasmapheresis donor eligibility, subjects will have other baseline assessments performed and if eligible, will receive the scheduled vaccinations,... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
11/14/2022
Locations: GCAM Eagle Pass Center, Eagle Pass, Texas +1 locations
Conditions: Tetanus
Register for Updates
Flucelvax (TIVc or QIVc) Pregnancy Registry
NCT03438487
Completed
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Gender:
FEMALE
Ages:
All
Trial Updated:
11/03/2022
Locations: Syneos Health, Wilmington, North Carolina
Conditions: Influenza, Human, Pregnancy, Birth Defect
Register for Updates